NTRA·Nasdaq·US

Natera

Natera develops and commercializes molecular diagnostic tests based on cell-free DNA and related precision-medicine technologies. Its product portfolio spans oncology, women’s health, and organ health, with revenue primarily driven by testing services and related licensing and other revenues.

Create free account

Recent Activity

Updated Oct 10, 2026

–Natera is partnering with Alliance Foundation Trials to support a Phase III trial testing MRD-guided treatment decisions for patients with ER-positive/HER2-negative breast cancer.

Past updates are part of the Pro plan.

Thematic Position

NTRA

Healthcare Innovation

Medical Devices

Diagnostics & ImagingLeader

Relationship Groups

Suppliers2

Customers1

Licensing1

Competitors10

Relationship details are part of the Pro plan.

Recent Discoveries

Recent discoveries are part of the Pro plan.

Ended Relationships

2 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

regulatory approvallicensing requirement

Foreign regulatory approvals required for Natera test commercialization in international markets

SEC 10-KFeb 27, 2026

The full regulatory passage is part of the Pro plan.

13 more · Regulatory and geopolitical insights are part of the Pro plan.